Company intelligence / Profile preview
VisiRose, Inc.
Knoxville, Tennessee, United Statesvisirose.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. In more than 500 patients across clinical trials in the U.S., India, Brazil, and Mexico, the treatment has demonstrated rapid infection resolution and improved patient outcomes[3][7].
- Therapeutic areas
- OphthalmologyInfectious Diseases
- Modalities
- Rose Bengal Sodium (RBS), a bioactive synthetic small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Miami Miller School of Medicine's Bascom Palmer Eye Institute
Beyond the preview
Go deeper on VisiRose, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VisiRose, Inc..